Molecular Testing in Thyroid Nodules and Differentiated Thyroid Cancer: A Comparison of the 2024 Korean Thyroid Association and 2025 American Thyroid Association Guidelines
Endocrinology and Metabolism · 31.10.2026 · 41 (5) · 587-590
DOI: 10.3803/enm.2026.3292 ↗Kurz gefasst
Editorial in der Zeitschrift Endocrinology and Metabolism, erschienen am 31.10.2026. Verfasst von Chan Kwon Jung. Beteiligte Einrichtung: Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul, Korea. ckjung@catholic.ac.kr. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The 2024 Korean Thyroid Association (KTA) guidelines and the 2025 American Thyroid Association (ATA) guideline for differentiated thyroid cancer (DTC) allow reassessment of how molecular testing informs clinical decisions, from thyroid nodule evaluation to the management of advanced DTC [1-5]
Autor:innen und Institutionen
- Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul, Korea. ckjung@catholic.ac.kr.
Zitieren
APA
Jung, C. K. (2026). Molecular Testing in Thyroid Nodules and Differentiated Thyroid Cancer: A Comparison of the 2024 Korean Thyroid Association and 2025 American Thyroid Association Guidelines. Endocrinology and Metabolism, 41(5), 587-590. https://doi.org/10.3803/enm.2026.3292
Vancouver
Jung CK. Molecular Testing in Thyroid Nodules and Differentiated Thyroid Cancer: A Comparison of the 2024 Korean Thyroid Association and 2025 American Thyroid Association Guidelines. Endocrinology and Metabolism. 2026;41(5):587-590. doi:10.3803/enm.2026.3292
BibTeX
@article{Jung2026,
author = {Jung, Chan Kwon},
title = {Molecular Testing in Thyroid Nodules and Differentiated Thyroid Cancer: A Comparison of the 2024 Korean Thyroid Association and 2025 American Thyroid Association Guidelines},
journal = {Endocrinology and Metabolism},
year = {2026},
volume = {41},
number = {5},
pages = {587--590},
doi = {10.3803/enm.2026.3292}
}
EUVIMED